Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1861 to 1875 of 7708 results

  1. Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]

    Awaiting development [GID-TA10605] Expected publication date: TBC

  2. Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]

    In development [GID-TA11036] Expected publication date: TBC

  3. Oral semaglutide for managing overweight and obesity [ID6188]

    Awaiting development [GID-TA11149] Expected publication date: TBC

  4. Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099]

    Awaiting development [GID-TA10972] Expected publication date: TBC

  5. Leriglitazone for treating X-linked andrenoleukodystrophy TS ID 9996

    Awaiting development [GID-TA11393] Expected publication date: TBC

  6. Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant TS ID 11868

    Awaiting development [GID-TA11361] Expected publication date: TBC

  7. Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]

    Awaiting development [GID-TA11300] Expected publication date: TBC

  8. Edaravone for treating amyotrophic lateral sclerosis TS ID 11869

    Awaiting development [GID-TA11362] Expected publication date: TBC

  9. Epilepsies in children, young people and adults (extraordinary review)

    In development [GID-NG10378] Expected publication date: TBC

  10. Lenacapavir for treating multidrug resistant HIV-1 ID6196

    Suggested remit: To appraise the clinical and cost effectiveness of lenacapavir within its marketing authorisation for treating multidrug resistant HIV-1 for wh...

  11. Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]

    In development [GID-TA11160] Expected publication date: TBC

  12. Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]

    Awaiting development [GID-TA11214] Expected publication date: TBC

  13. Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]

    In development [GID-TA10024] Expected publication date: 28 June 2017

  14. Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]

    In development [GID-TA10606] Expected publication date: TBC